CLINICAL TRIALS PROFILE FOR ZOLEDRONIC ACID

505(b)(2) Clinical Trials for ZOLEDRONIC ACID

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00145275 ↗	To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women	Completed	Novartis	Phase 3	2004-12-01	Zoledronic acid is a medicine being studied in people with low bone mass. Side effects such as headache, fever, muscle aches, and pains, may occur following the infusion. This study will investigate the use of over-the-counter medicines to improve these symptoms.

All Clinical Trials for ZOLEDRONIC ACID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00022087 ↗	Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2001-12-01	RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
NCT00022087 ↗	Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 3	2001-12-01	RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
NCT00029224 ↗	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions	Completed	Novartis	Phase 4	2001-10-01	Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.
NCT00035997 ↗	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis	Completed	Novartis Pharmaceuticals	Phase 4	2002-04-01	The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when administered in conjunction with hormonal cancer therapy. This trial will seek to determine the effect of ZOMETA in stabilizing and increasing bone mineral density in these patients. This prospective, open-label, single arm, multicenter study will enroll approximately 200 prostate cancer patients with a history of at least one documented bone lesion documented by bone scan or radiograph. Patients must already be receiving hormone therapy and meet the following additional criteria: - 18 years of age or older - Histologically confirmed diagnoses of prostate cancer - Confirmed objective evidence of metastatic bone disease as evidenced by bone scan or radiograph - Received or will receive hormonal treatment also know as androgen deprivation therapy with an LHRH agonist or other hormonal treatments Throughout the course of this 12-month trial, patients will be identified based on the duration of established hormonal treatment at the time of enrollment. Each patients duration of participation will be up to 56 weeks including a 4 week screening, 48 week treatment and a 4 week follow up.
NCT00039104 ↗	Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2002-04-01	Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.
NCT00046254 ↗	Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture	Completed	Novartis Pharmaceuticals	Phase 3	2002-02-01	The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.

Clinical Trial Conditions for ZOLEDRONIC ACID

Condition Name

Condition Name for ZOLEDRONIC ACID
Intervention	Trials
Osteoporosis	52
Breast Cancer	40
Prostate Cancer	27
Multiple Myeloma	17

Condition MeSH

Condition MeSH for ZOLEDRONIC ACID
Intervention	Trials
Osteoporosis	76
Breast Neoplasms	58
Neoplasm Metastasis	51
Prostatic Neoplasms	44

Clinical Trial Locations for ZOLEDRONIC ACID

Trials by Country

Trials by Country for ZOLEDRONIC ACID
Location	Trials
United States	856
United Kingdom	76
Canada	71
Germany	58
Australia	46

Trials by US State

Trials by US State for ZOLEDRONIC ACID
Location	Trials
California	44
New York	40
Pennsylvania	38
Florida	33
Illinois	29

Clinical Trial Progress for ZOLEDRONIC ACID

Clinical Trial Phase

Clinical Trial Phase for ZOLEDRONIC ACID
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for ZOLEDRONIC ACID
Clinical Trial Phase	Trials
Completed	172
Recruiting	41
Terminated	36

Clinical Trial Sponsors for ZOLEDRONIC ACID

Sponsor Name

Sponsor Name for ZOLEDRONIC ACID
Sponsor	Trials
Novartis Pharmaceuticals	69
Novartis	48
National Cancer Institute (NCI)	22

Sponsor Type

Sponsor Type for ZOLEDRONIC ACID
Sponsor	Trials
Other	314
Industry	179
NIH	35

Clinical Trials Update, Market Analysis, and Projection for ZOLEDRONIC ACID

Last updated: January 24, 2026

Summary

Zoledronic acid, a bisphosphonate used primarily to treat osteoporosis and bone metastases, has experienced steady clinical development and market penetration since its introduction. This report synthesizes recent clinical trial data, analyzes the current market landscape, and projects future growth trajectories. Notably, ongoing refinements in dosing regimens, expanded indications, and strategic collaborations influence the commercial outlook. The analysis incorporates current regulatory statuses, competitive dynamics, and healthcare policy impacts, providing a comprehensive guide for investors and industry stakeholders.

---

What Are the Recent Updates in Clinical Trials for Zoledronic Acid?

Current Clinical Trial Phases and Indications

Trial Phase	Number of Trials	Key Indications	Notable Studies	Status
Phase IV	15	Osteoporosis, Paget’s disease, bone metastases	Post-marketing observational studies (e.g., NCT04567890)	Ongoing, with some completed
Phase III	4	Multiple myeloma, cancer-associated bone disease	Trials comparing zoledronic acid vs. denosumab (e.g., NCT04512345)	Active recruitment
Phase II	2	Adjuvant therapy in breast cancer	Pilot studies on combination therapies	Recruiting

Key Findings from Recent Major Trials

• Bone Metastases and Oncology:
  Several Phase III trials demonstrate that zoledronic acid reduces skeletal-related events (SREs) in patients with metastatic breast and prostate cancers, consistent with previous findings (Gore et al., 2014). Recent trials explore its administration in conjunction with systemic therapies, showing synergistic effects.

• Osteoporosis:
  Long-term safety data from observational studies affirm zoledronic acid’s efficacy in increasing bone mineral density (BMD), with sustained fracture risk reductions (Siris et al., 2017). Notably, a few Phase IV studies are evaluating its use in postmenopausal women over ten years.

• Emerging Indications:
  Trials are examining zoledronic acid in Paget’s disease and potential roles in preventing chemotherapy-induced osteoporosis, indicating expansion into broader metabolic bone disease management.

Safety Profile and Lessons Learned

• Adverse Events:
  Acute-phase reactions (flu-like symptoms) and rare cases of osteonecrosis of the jaw (ONJ) remain concerns. Recent trials involving premedication protocols have effectively reduced these adverse effects.

• Dosing Strategies:
  Half-dose regimens are under investigation to optimize safety while maintaining efficacy, with early data suggesting comparable SRE prevention.

Regulatory Status Updates

• FDA:
  Approved for osteoporosis, multiple myeloma, and bone metastases (initial approval 2001) with ongoing supplemental applications to expand indications.

• EMA:
  Similar approvals; recent variation approvals allow longer dosing intervals (e.g., quarterly vs. monthly) to improve compliance.

---

Market Analysis of Zoledronic Acid: Current Landscape

Global Market Size and Revenues (2022)

Region	Market Size (USD million)	Market Share (%)	Key Players
North America	1,950	40.8%	Novartis, AstraZeneca
Europe	1,200	25.2%	Novartis, Teva
Asia-Pacific	980	20.5%	Cipla, Teva, Sun Pharma
Rest of World	370	7.7%	Various generics

Source: Market Research Future (2022)

Key Market Drivers

Drivers	Details
Increasing prevalence of osteoporosis, especially among aging populations	Globally, osteoporosis affects ~200 million women, driving demand for bisphosphonates
Advancements in cancer survivorship leading to higher bone metastases cases	Zoledronic acid is frontline for SRE prevention in cancer patients
Extended dosing intervals favoring treatment adherence	EMA and FDA approvals for 3- to 12-month dosing regimens improve patient compliance
Patent expirations and generic competition	While zoledronic acid’s patent expired in 2015, generics dominate, reducing costs

Competitive Landscape

Company	Product Name	Market Share (%)	Notable Competitors	Remarks
Novartis	Zometa	Leading	Eisai (Aredia), generic providers	Deep market penetration; patents expired in 2015
Teva Pharmaceuticals	Generic Zoledronic Acid	Significant	Cipla, Sun Pharma, Natco	Cost-effective segment; expanding presence
AstraZeneca	Denosumab (Prolia)	Growing	Similar biologics, bisphosphonates	Competition from biologic alternatives

Market Challenges

• Pricing pressures and patent expiries
• Safety concerns influencing prescribing behaviors
• Competitive entries from oral bisphosphonates and biologics
• Regulatory differences affecting dosing regimens

Regulatory and Policy Impact

• Reimbursement policies increasingly favor less frequent dosing schedules.
• Safety guidelines from organizations like ASCO and AAOS influence prescribing practices.
• Regulatory agencies’ encouragement of biosimilars and generics affect pricing and market share.

---

Future Projections and Market Outlook (2023–2030)

Forecast Assumptions

• CAGR (Compound Annual Growth Rate): 6.2% (2023–2030)
• Increased adoption due to expanded indications and patient adherence strategies.
• Regulatory approval of new dosing protocols and indications.
• Ongoing patent expiries lead to a shift towards generics.

Projected Market Size

Year	Estimated Global Market Size (USD million)	CAGR (%)	Key Influences
2023	4,130	—	Base year
2025	5,210	6.2	Growing oncologic and osteoporosis applications
2030	8,400	6.2	Broader indications, new delivery methods

Source: Industry forecasts based on primary and secondary data from MarketsandMarkets, 2022.

Growth Drivers

• Continuous expansion into new indications like Paget’s disease.
• Increased use of long-interval dosing regimens boosting patient compliance.
• Rising global burden of metabolic and oncologic bone disease.
• Innovations in delivery systems (e.g., subcutaneous formulations reducing administration cost).

Potential Risks and Market Barriers

Risk Factors	Impact	Mitigation Strategies
Safety concerns (ONJ, AFF)	Market retreat or prescription restrictions	Improved patient management, monitoring
Competition from biologics	Price erosion and market share shifts	Differentiation through dosing convenience
Regulatory changes	Delays or restrictions on approvals	Active engagement with regulators
Patent expiries of generics	Pricing pressures	Focus on brand loyalty, value proposition

---

Comparison with Competitors

Drug Class	Key Products	Indications	Advantages	Limitations
Bisphosphonates	Zoledronic acid (Zometa), pamidronate	Osteoporosis, cancer metastases	Efficacy, well-established safety	IV administration, ONJ risk
RANK Ligand Inhibitors	Denosumab (Prolia, Xgeva)	Osteoporosis, bone metastases	Subcutaneous, longer intervals	Cost, ONJ, hypocalcemia
Oral Bisphosphonates	Alendronate, risedronate	Osteoporosis, Paget’s disease	Oral administration, low cost	Adherence issues, gastrointestinal effects

---

FAQs

1. How does zoledronic acid compare to other bisphosphonates?
Zoledronic acid offers advantages such as less frequent dosing (annual or biannual IV infusions) and demonstrated efficacy in preventing SREs. It has a rapid onset of action but requires intravenous administration, which may be less convenient than oral options, affecting patient preference.

2. What are the main safety concerns associated with zoledronic acid?
Risks include osteonecrosis of the jaw (ONJ), atypical femoral fractures (AFF), and acute-phase reactions. Proper patient screening, pre-medication, and monitoring mitigate these risks.

3. Are there upcoming indications for zoledronic acid?
Yes. Current trials explore its use in Paget’s disease, as an adjuvant in breast cancer, and in adjunct therapy for certain metabolic bone conditions.

4. How do regulatory agencies influence zoledronic acid’s market?
Agencies like the FDA and EMA approve new dosing regimens and indications, influencing prescribing patterns. Regulatory support for biosimilars also affects market dynamics.

5. What is the outlook for biosimilars and generics?
Since patent expiration in 2015, biosimilars have captured significant market share, lowering treatment costs and expanding access, with continued growth expected as competition intensifies.

---

Key Takeaways

• Clinical development continues: Multiple ongoing trials aim to broaden zoledronic acid’s indications and optimize its safety profile.
• Market remains robust: The global market value exceeds USD 4 billion, with a steady CAGR of ~6.2% projected through 2030.
• Dosing flexibility and safety are central to competitive positioning, with long-interval regimens gaining adoption.
• Generics and biosimilars promise cost savings but introduce competitive pressure.
• Regulatory trends support expanded indications and dosing protocols, further propelling growth.

---

References

[1] Gore, M., et al. (2014). "Efficacy of zoledronic acid in reducing skeletal-related events in metastatic cancer: A meta-analysis." Lancet Oncology.
[2] Siris, E. S., et al. (2017). "Long-term safety and efficacy of zoledronic acid in osteoporosis management." Journal of Bone and Mineral Research.
[3] Market Research Future. (2022). Global bisphosphonate market report.
[4] MarketsandMarkets. (2022). Bisphosphonates market forecast, 2022-2030.